Literature DB >> 7042428

Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion.

J C Pickup, G C Viberti, R W Bilous, H Keen, K G Alberti, P D Home, C Binder.   

Abstract

To assess the rate of metabolic deterioration and potential risks of failure of continuous subcutaneous insulin infusion during basal insulin delivery, we deliberately stopped infusion in nine insulin dependent diabetics. Plasma glucose, blood 3-hydroxybutyrate and plasma free insulin were measured for 9 h whilst the patients remained supine and fasting. Mean plasma glucose remained unchanged at normal fasting levels for the first hour, then rose to plateau at about 10 mmol/l until the end of the experiment. The final plateau level of glucose varied from patient to patient; two C-peptide secreting diabetics plateaued at low glucose levels. In contrast, blood 3-hydroxybutyrate rose progressively, without plateauing. PLasma free insulin concentrations fell during the withdrawal period and there was a highly significant negative correlation between free insulin and 3-hydroxybutyrate. No patient was more than mildly unwell after 9 h of insulin deprivation. We conclude that under these experimental conditions there is glycaemic autoregulation and that ketones may sometimes be a more appropriate monitor of insulin deficiency or loss of diabetic control than is glucose. Accidental failure of continuous subcutaneous insulin infusion and interruption of basal delivery in resting and fasting diabetics will probably not cause dangerous metabolic or clinical deterioration.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7042428     DOI: 10.1007/bf00283748

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  18 in total

1.  A simple method for the determination of serum free insulin levels in insulin-treated patients.

Authors:  S Nakagawa; H Nakayama; T Sasaki; K Yoshino; Y Y Yu
Journal:  Diabetes       Date:  1973-08       Impact factor: 9.461

2.  Blood glucose regulates the effects of insulin and counterregulatory hormones on glucose production in vivo.

Authors:  L Saccà; P E Cryer; R S Sherwin
Journal:  Diabetes       Date:  1979-06       Impact factor: 9.461

3.  Continuous subcutaneous insulin infusion in the treatment of diabetes mellitus.

Authors:  J C Pickup; H Keen; G C Viberti; M C White; E M Kohner; J A Parsons; K G Alberti
Journal:  Diabetes Care       Date:  1980 Mar-Apr       Impact factor: 19.112

4.  Long-term continuous subcutaneous insulin infusion in diabetics at home.

Authors:  J C Pickup; M C White; H Keen; J A Parsons; K G Alberti
Journal:  Lancet       Date:  1979-10-27       Impact factor: 79.321

5.  Reduction to normal of plasma glucose in juvenile diabetes by subcutaneous administration of insulin with a portable infusion pump.

Authors:  W V Tamborlane; R S Sherwin; M Genel; P Felig
Journal:  N Engl J Med       Date:  1979-03-15       Impact factor: 91.245

6.  Outpatient treatment of juvenile-onset diabetes with a preprogrammed portable subcutaneous insulin infusion system.

Authors:  W V Tamborlane; R S Sherwin; M Genel; P Felig
Journal:  Am J Med       Date:  1980-02       Impact factor: 4.965

7.  Ketoacidosis in pancreatectomized man.

Authors:  A J Barnes; S R Bloom; K Goerge; G M Alberti; P Smythe; F P Alford; D J Chisholm
Journal:  N Engl J Med       Date:  1977-06-02       Impact factor: 91.245

8.  Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.

Authors:  J C Pickup; H Keen; J A Parsons; K G Alberti
Journal:  Br Med J       Date:  1978-01-28

9.  Hyperglycemia per se (insulin and glucagon withdrawn) can inhibit hepatic glucose production in man.

Authors:  J E Liljenquist; G L Mueller; A D Cherrington; J M Perry; D Rabinowitz
Journal:  J Clin Endocrinol Metab       Date:  1979-01       Impact factor: 5.958

10.  Continuous subcutaneous insulin infusion: improved blood-glucose and intermediary-metabolite control in diabetics.

Authors:  J C Pickup; H Keen; J A Parsons; K G Alberti; A S Rowe
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

View more
  13 in total

1.  Innovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system).

Authors:  David C Klonoff; Charles L Zimliki; Lcdr Alan Stevens; Patricia Beaston; Arleen Pinkos; Sally Y Choe; Guillermo Arreaza-Rubín; William Heetderks
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

2.  Ketone production in children with type 1 diabetes, ages 4-14 years, with and without nocturnal insulin pump suspension.

Authors:  R Paul Wadwa; H Peter Chase; Dan Raghinaru; Bruce A Buckingham; Irene Hramiak; David M Maahs; Laurel Messer; Trang Ly; Tandy Aye; Paula Clinton; Craig Kollman; Roy W Beck; John Lum
Journal:  Pediatr Diabetes       Date:  2016-07-12       Impact factor: 4.866

3.  Hyperkalaemia after interruption of CSII.

Authors:  J C Pickup
Journal:  Diabetologia       Date:  1986-11       Impact factor: 10.122

4.  Intrauterine death during continuous subcutaneous infusion of insulin.

Authors:  J M Steel; C P West
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-15

5.  A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin.

Authors:  A J Scheen; G Krzentowski; M Castillo; P J Lefèbvre; A S Luyckx
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

6.  Target fasting glycaemia for pump-treated type-I diabetics.

Authors:  E A Chantelau; G E Sonnenberg; F Best; L G Heding; M Berger
Journal:  Klin Wochenschr       Date:  1984-04-02

7.  Diabetic ketoacidosis associated with outpatient treatment using continuous subcutaneous insulin infusion.

Authors:  A J Boulton; G Knight; J Drury; J D Ward
Journal:  Postgrad Med J       Date:  1983-07       Impact factor: 2.401

8.  A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control.

Authors:  G Krzentowski; A Scheen; M Castillo; A S Luyckx; P J Lefèbvre
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

9.  Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk.

Authors:  Pratik Choudhary; John Shin; Yongyin Wang; Mark L Evans; Peter J Hammond; David Kerr; James A M Shaw; John C Pickup; Stephanie A Amiel
Journal:  Diabetes Care       Date:  2011-09       Impact factor: 19.112

10.  Relapse of diabetic ketoacidosis secondary to insulin pump malfunction diagnosed by capillary blood 3-hydroxybutyrate: a case report.

Authors:  John Scott Baird
Journal:  Cases J       Date:  2009-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.